Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

ProteoTech and Tasly Pharmaceuticals to Jointly Develop Alzheimer’s Disease Drug

By Pharmaceutical Processing | October 4, 2010

 Tasly
Pharmaceutical Co., Ltd.  (Tianjin, China) and ProteoTech, Inc. (Kirkland,
WA, USA) today announced an agreement to co-develop ProteoTech’s novel small
molecule therapeutic, Exebryl-1(R), for the treatment of mild-to-moderate
Alzheimer’s disease. Exebryl-1(R) has been shown to inhibit beta-amyloid
protein aggregate formation in brain, as well as disaggregate amyloid plaques
that are already present.  The drug has also shown specificity against tau
protein aggregates and may be the first therapeutic targeting beta-amyloid and
tau protein associated with this disease.

The
collaboration will focus on moving the clinical development of this drug though
the regulatory process in China
and the US.
 Terms of the deal were not disclosed but will include an upfront payment,
development costs and research funding to ProteoTech according to Manuel
Menendez, Managing Partner of Nobel Pacific, who acted as an advisor to both
companies. Tasly will gain rights for Exebryl-1(R) for China and ProteoTech will retain rights for the United States
and the rest of the world.

“We are
very happy with this opportunity to work with the team at ProteoTech and we
feel that Exebryl-1(R) will become a very important medication in China against
the growing epidemic of Alzheimer’s disease” stated Dr. Henry Sun, Vice
President of Tasly Group and President of Tasly Pharmaceuticals, Inc.

ProteoTech CEO,
Steve Runnels said “The opportunity for this collaboration with a major
international pharmaceutical company is very exciting for us. We are very fortunate
to have Tasly as a partner and their experience in drug development, especially
in China,
provides an opportunity to accelerate Exebryl-1(R) through clinical
development.  We look forward to a successful Exebryl-1(R) collaboration
with Tasly and the potential development of other promising technologies in our
pipeline as well.”

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE